Return to homepagePandemic Pact

ACE2-ORG. Development of a human cellular platform unveiling Angiotensin-converting enzyme 2 (ACE2) - sars-CoV-2 interactions

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00278

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Nuria Monserrat

  • Research Location

    Spain

  • Lead Research Institution

    Instituto de Bioingeniería de Cataluña

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

There are no models allowing to unveil the molecular pathways and cellular responses differently regulated upon SARS-CoV-2 infection in human tissues. Organoid technology represents and affordable solution to COVID-19 research. Our consortia is able to infect a plethora of human organoids opening the door for drug screening for COVID19 treatment. These results are part of a present manuscript under review in Cell. Bases in our current finding our aim is to understand, identify and target ACE2-SARS. COV2 cellular responses exploiting kidney and heart organoids exposed to systemic conditions worsening COVID19 disease (e.e. Diabetes). Using scRNA sequentiation we will unveil unique and common cellular responses upon SARS-coV-2 infection and use primary cell cultures and retrospective COVID19 necropsies for validation. This approach will identify top ranked pathwys differentially regulated upong SARS-CoV.2 infection in control and diabetic backgrounds.